BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 28403564)

  • 1. Location of residual viable tumor cells after neoadjuvant chemotherapy: A new concept with high prognostic performance in osteosarcoma.
    Kim SH; Shin KH; Moon SH; Kong Y; Suh JS; Yang WI
    J Surg Oncol; 2017 May; 115(6):752-759. PubMed ID: 28403564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients].
    Bielack S; Kempf-Bielack B; Schwenzer D; Birkfellner T; Delling G; Ewerbeck V; Exner GU; Fuchs N; Göbel U; Graf N; Heise U; Helmke K; von Hochstetter AR; Jürgens H; Maas R; Münchow N; Salzer-Kuntschik M; Treuner J; Veltmann U; Werner M; Winkelmann W; Zoubek A; Kotz R
    Klin Padiatr; 1999; 211(4):260-70. PubMed ID: 10472560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma.
    Tsuda Y; Tsoi K; Parry MC; Stevenson JD; Fujiwara T; Sumathi V; Jeys LM
    Bone Joint J; 2020 Jun; 102-B(6):795-803. PubMed ID: 32475245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
    Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
    Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
    Hong S; Shin SJ; Jung M; Jeong J; Lee YJ; Shin KH; Roh JK; Rha SY
    Oncology; 2011; 80(1-2):107-17. PubMed ID: 21677455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy.
    Hattinger CM; Michelacci F; Sella F; Magagnoli G; Benini S; Gambarotti M; Palmerini E; Picci P; Serra M; Ferrari S
    Histopathology; 2015 Sep; 67(3):338-47. PubMed ID: 25600168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between Prognostic Factors and the Histopathological Response to Neoadjuvant Chemotherapy in Osteosarcoma: A Retrospective Study.
    Prabowo Y; Setiawan I; Kamal AF; Kodrat E; Labib Zufar ML
    Int J Surg Oncol; 2021; 2021():8843325. PubMed ID: 33996154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities.
    Serra M; Scotlandi K; Reverter-Branchat G; Ferrari S; Manara MC; Benini S; Incaprera M; Bertoni F; Mercuri M; Briccoli A; Bacci G; Picci P
    J Clin Oncol; 2003 Feb; 21(3):536-42. PubMed ID: 12560446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant therapy of osteosarcoma--A Phase II trial: Southwest Oncology Group study 9139.
    Zalupski MM; Rankin C; Ryan JR; Lucas DR; Muler J; Lanier KS; Budd GT; Biermann JS; Meyers FJ; Antman K
    Cancer; 2004 Feb; 100(4):818-25. PubMed ID: 14770440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effectiveness and safety of polyethylene glycol liposome doxorubicin in the treatment of osteosarcoma].
    Yang YK; Xu HR; Huang Z; Li Y; Niu XH
    Zhonghua Zhong Liu Za Zhi; 2020 Aug; 42(8):692-696. PubMed ID: 32867464
    [No Abstract]   [Full Text] [Related]  

  • 11. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
    Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
    J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients.
    Nataraj V; Batra A; Rastogi S; Khan SA; Sharma MC; Vishnubhatla S; Bakhshi S
    J Surg Oncol; 2015 Nov; 112(6):662-8. PubMed ID: 26381138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of large osteosarcoma in children: new approach.
    Kobys VL; Konovalenko VF; Repinа NV; Golovko TS; Gulak LO; Tarasova TO; Zaharycheva EV; Matyushok OF
    Exp Oncol; 2013 Jun; 35(2):105-8. PubMed ID: 23828385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative tumor burden predicts metastasis-free survival in pediatric osteosarcoma.
    Lee JA; Kim MS; Kim DH; Lim JS; Yoo JY; Koh JS; Lee SY; Jeon DG; Park KD
    Pediatr Blood Cancer; 2008 Feb; 50(2):195-200. PubMed ID: 18061933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide.
    Lin F; Wang Q; Yu W; Tang L; Zheng S; Sun Y; Shen Z; Yao Y; Dong Y
    Asia Pac J Clin Oncol; 2011 Sep; 7(3):270-5. PubMed ID: 21884438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas?
    Fan Z; Patel S; Lewis VO; Guadagnolo BA; Lin PP
    Clin Orthop Relat Res; 2015 Nov; 473(11):3604-11. PubMed ID: 26197952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic implication of adjuvant/neoadjuvant chemotherapy consisting of doxorubicin and ifosfamide in patients with extraskeletal osteosarcoma.
    Wakamatsu T; Kakunaga S; Takenaka S; Outani H; Hamada K; Imura Y; Hori Y; Naka N; Kudawara I; Yoshikawa H; Ueda T
    Int J Clin Oncol; 2019 Oct; 24(10):1311-1319. PubMed ID: 31197555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between apparent diffusion coefficient and histopathology subtypes of osteosarcoma after neoadjuvant chemotherapy.
    Wang J; Sun M; Liu D; Hu X; Pui MH; Meng Q; Gao Z
    Acta Radiol; 2017 Aug; 58(8):971-976. PubMed ID: 27852643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of preoperative radiotherapy in nonmetastatic high-grade osteosarcoma of the extremities for limb-sparing surgery.
    Dinçbaş FO; Koca S; Mandel NM; Hiz M; Dervişoğlu S; Seçmezacar H; Oksüz DC; Ceylaner B; Uzel B
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):820-8. PubMed ID: 15936566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan.
    Kudawara I; Aoki Y; Ueda T; Araki N; Naka N; Nakanishi H; Matsumine A; Ieguchi M; Mori S; Myoui A; Kuratsu S; Hashimoto N; Yoshikawa H
    J Chemother; 2013 Feb; 25(1):41-8. PubMed ID: 23433444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.